Gates MRI- COD-01-T01-01 Amendment 1

Targeted Disease(s):

Purpose of Study:

A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.

Study Dates:
September 1, 2020 - Ongoing

Type of Study:

Study Design:
Controlled Design

Study Location:

Lead Institution:
Allergy & Asthma Medical Group and Research Center A P.C

Funding Source:
Bill & Melinda Gates Medical Research Institute Identifier:

Register for Trial
Asthma Educator Institute
, | Jul 11, 2022
COPD Educator Course
, | Oct 06, 2022